| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2012.729820 |
| P698 | PubMed publication ID | 23035697 |
| P50 | author | Jordi Vila | Q55030523 |
| P2093 | author name string | Jerónimo Pachón | |
| P2860 | cites work | Updated functional classification of beta-lactamases | Q24644798 |
| Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454 | Q28205309 | ||
| Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces | Q28249751 | ||
| Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review | Q28258478 | ||
| Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance | Q29617469 | ||
| Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections | Q33416170 | ||
| Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii | Q33676191 | ||
| Detection of KPC in Acinetobacter spp. in Puerto Rico | Q33676198 | ||
| Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (forme | Q33820401 | ||
| Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii | Q33868250 | ||
| Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. | Q33882361 | ||
| Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. | Q33901939 | ||
| Practice guidelines for the management of bacterial meningitis | Q33982444 | ||
| Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea | Q48018252 | ||
| Evolution of antimicrobial resistance of Acinetobacter baumannii in a university hospital. | Q51024890 | ||
| In vitro postantibiotic effect of colistin on multidrug-resistant Acinetobacter baumannii. | Q51091548 | ||
| Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis. | Q51752213 | ||
| The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. | Q51791235 | ||
| Thiophenyl oxime-derived phosphonates as nano-molar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. | Q53420886 | ||
| Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. | Q53851336 | ||
| Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. | Q54031283 | ||
| Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. | Q54358887 | ||
| Emergence of NDM-1-producing Acinetobacter baumannii in China. | Q54365552 | ||
| Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. | Q54426692 | ||
| Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China. | Q54439946 | ||
| Acinetobacter baumannii Resistant to Colistin With Impaired Virulence: A Case Report From France | Q56572609 | ||
| Efficacy of cecropin A-melittin peptides on a sepsis model of infection by pan-resistant Acinetobacter baumannii | Q57179932 | ||
| Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii | Q57179939 | ||
| Prevalencia de los genes tetA y tetB como mecanismo de resistencia a tetraciclina y minociclina en aislamientos clínicos de Acinetobacter baumannii | Q57657482 | ||
| Mechanism of action of and resistance to quinolones | Q58057075 | ||
| Acinetobacter baumannii resistant to everything: what should we do? | Q58386822 | ||
| Pre-clinical studies of a new quinolone (UB-8902) against Acinetobacter baumannii resistant to ciprofloxacin | Q58386917 | ||
| Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii | Q59245528 | ||
| Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii | Q33993176 | ||
| Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii | Q34109543 | ||
| Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections | Q34308017 | ||
| Potent Synergy and Sustained Bactericidal Activity of a Vancomycin-Colistin Combination versus Multidrug-Resistant Strains of Acinetobacter baumannii | Q34309445 | ||
| Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production | Q34309451 | ||
| Rapid development of Acinetobacter baumannii resistance to tigecycline | Q34581377 | ||
| NDM-2 carbapenemase in Acinetobacter baumannii from Egypt | Q34660446 | ||
| Acinetobacter baumannii: emergence of a successful pathogen | Q34795807 | ||
| Insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. | Q35005140 | ||
| Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients | Q35065863 | ||
| The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. | Q35139454 | ||
| Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. | Q35270405 | ||
| Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center | Q35364446 | ||
| Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections | Q35462009 | ||
| The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace | Q35905605 | ||
| Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections | Q36095874 | ||
| The epidemiology and control of Acinetobacter baumannii in health care facilities | Q36382140 | ||
| In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria | Q36669161 | ||
| Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. | Q36746061 | ||
| Therapeutic options for Acinetobacter baumannii infections | Q37099006 | ||
| Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. | Q37119524 | ||
| Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence | Q37147563 | ||
| Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. | Q37274659 | ||
| Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization | Q37302581 | ||
| Photodynamic therapy for Acinetobacter baumannii burn infections in mice | Q37333045 | ||
| Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system | Q37333088 | ||
| A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline | Q37374012 | ||
| Long-term control of hospital-wide, endemic multidrug-resistant Acinetobacter baumannii through a comprehensive "bundle" approach. | Q37439554 | ||
| Intrathecal colistin for drug-resistant Acinetobacter baumannii central nervous system infection: a case series and systematic review | Q37581030 | ||
| Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature | Q37628241 | ||
| New information about the polymyxin/colistin class of antibiotics | Q37636150 | ||
| Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options | Q37960325 | ||
| Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies | Q37996299 | ||
| Impact of inappropriate antimicrobial therapy on outcome in patients with hospital-acquired pneumonia caused by Acinetobacter baumannii | Q38483778 | ||
| Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria | Q39384855 | ||
| Genetic features of CTX-M-15-producing Acinetobacter baumannii from Haiti | Q39660188 | ||
| Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter | Q39749477 | ||
| Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system | Q39922949 | ||
| Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem | Q40290852 | ||
| Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam | Q40651849 | ||
| In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest | Q41811933 | ||
| AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii | Q41859877 | ||
| In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection | Q41861884 | ||
| Colistin heteroresistance in acinetobacter and its association with previous colistin therapy | Q41912289 | ||
| The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections | Q41984345 | ||
| Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges | Q42567062 | ||
| A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae | Q42664352 | ||
| Detection of CTX-M-15-producing and carbapenem-resistant Acinetobacter baumannii strains from urine from an Indian hospital | Q42788447 | ||
| Comprehensive assessment of tigecycline activity tested against a worldwide collection of Acinetobacter spp. (2005–2009) | Q42855427 | ||
| Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia | Q42908865 | ||
| Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model | Q43081018 | ||
| Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis | Q43127750 | ||
| Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis | Q43152520 | ||
| Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis | Q43229434 | ||
| Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective | Q43237048 | ||
| Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii. | Q43269078 | ||
| Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains | Q43552346 | ||
| In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates | Q43635292 | ||
| Nosocomial outbreak of infection with pan-drug-resistant Acinetobacter baumannii in a tertiary care university hospital | Q43756833 | ||
| Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. | Q43961916 | ||
| Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin | Q43983010 | ||
| Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. | Q44123853 | ||
| The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii | Q44185335 | ||
| Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam | Q44266822 | ||
| Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. | Q44417867 | ||
| Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group | Q44419135 | ||
| Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial | Q44467386 | ||
| In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. | Q44575246 | ||
| Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study | Q44609136 | ||
| Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings | Q44936182 | ||
| Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain. A nationwide multicenter study: GEIH-Ab project (2000) | Q44944397 | ||
| Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. | Q46006904 | ||
| Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline | Q46083242 | ||
| Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii | Q46193054 | ||
| Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model | Q46331390 | ||
| Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia | Q46335722 | ||
| Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant Acinetobacter baumannii strains from different European hospitals | Q46420938 | ||
| Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia | Q46577225 | ||
| Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009. | Q46592733 | ||
| Successful treatment of Acinetobacter meningitis with meropenem and rifampicin | Q46620852 | ||
| Potential for underdosing and emergence of resistance in Acinetobacter baumannii during treatment with colistin. | Q46779892 | ||
| Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections | Q46824068 | ||
| Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study | Q46929397 | ||
| In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii | Q47591529 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Acinetobacter baumannii | Q3241189 |
| P304 | page(s) | 2319-2336 | |
| P577 | publication date | 2012-10-04 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Therapeutic options for Acinetobacter baumannii infections: an update | |
| P478 | volume | 13 |
| Q58760386 | A multiplex loop-mediated isothermal amplification assay for rapid screening of and D carbapenemase gene |
| Q33709547 | AB5075, a Highly Virulent Isolate of Acinetobacter baumannii, as a Model Strain for the Evaluation of Pathogenesis and Antimicrobial Treatments. |
| Q28550341 | Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model |
| Q40315976 | An Amphipathic Undecapeptide with All d-Amino Acids Shows Promising Activity against Colistin-Resistant Strains of Acinetobacter baumannii and a Dual Mode of Action. |
| Q89494971 | COLR Acinetobacter baumannii sRNA Signatures: Computational Comparative Identification and Biological Targets |
| Q38243475 | Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. |
| Q40618477 | Characterization of a highly virulent and antimicrobial-resistant Acinetobacter baumannii strain isolated from diseased chicks in China |
| Q60919466 | Colistin Resistant : Genomic and Transcriptomic Traits Acquired Under Colistin Therapy |
| Q37124050 | Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. |
| Q40598628 | DNA fingerprinting and antimicrobial susceptibility pattern of clinical and environmental Acinetobacter baumannii isolates: a multicentre study. |
| Q41036115 | Differential roles of antimicrobials in the acquisition of drug resistance through activation of the SOS response in Acinetobacter baumannii |
| Q98226279 | Drugs for Gram-Negative Bugs From 2010-2019: A Decade in Review |
| Q59801603 | Efficacy of φkm18p phage therapy in a murine model of extensively drug-resistant infection |
| Q34597581 | Evaluation of a loop-mediated isothermal amplification-based methodology to detect carbapenemase carriage in Acinetobacter clinical isolates. |
| Q38789675 | Glucose availability enhances lipopolysaccharide production and immunogenicity in the opportunistic pathogen Acinetobacter baumannii. |
| Q37000834 | Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates |
| Q51744041 | IL-33 Treatment Attenuates the Systemic Inflammation Reaction in Acinetobacter baumannii Pneumonia by Suppressing TLR4/NF-κB Signaling. |
| Q35202480 | Impact of Acinetobacter baumannii superoxide dismutase on motility, virulence, oxidative stress resistance and susceptibility to antibiotics |
| Q37358693 | In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant Acinetobacter baumannii. |
| Q37122285 | In Vivo Application of Bacteriophage as a Potential Therapeutic Agent To Control OXA-66-Like Carbapenemase-Producing Acinetobacter baumannii Strains Belonging to Sequence Type 357. |
| Q62857064 | In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii |
| Q42689542 | MALDI-TOF mass spectrometry: An emerging tool for unequivocal identification of non-fermenting Gram-negative bacilli. |
| Q34982516 | Multi-center evaluation of the VITEK® MS system for mass spectrometric identification of non-Enterobacteriaceae Gram-negative bacilli. |
| Q38805100 | New molecules and adjuvants in the treatment of infections by Acinetobacter baumannii. |
| Q36986737 | Potentiation of antimicrobial photodynamic inactivation mediated by a cationic fullerene by added iodide: in vitro and in vivo studies |
| Q37648715 | Structural basis for fragmenting the exopolysaccharide of Acinetobacter baumannii by bacteriophage ΦAB6 tailspike protein |
| Q58585220 | Synergistic Activity of Niclosamide in Combination With Colistin Against Colistin-Susceptible and Colistin-Resistant and |
| Q45076608 | TEM-1 β-lactamase as a source of resistance to sulbactam in clinical strains of Acinetobacter baumannii |
| Q35746123 | Therapeutic efficacy of lysophosphatidylcholine in severe infections caused by Acinetobacter baumannii. |
| Q39391864 | Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period |
| Q53806892 | Use of adjuvants in the treatment of Acinetobacter baumannii. |
Search more.